Recursion Pharmaceuticals Stock (NASDAQ:RXRX)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$6.26

52W Range

$3.79 - $12.36

50D Avg

$5.09

200D Avg

$6.25

Market Cap

$2.76B

Avg Vol (3M)

$28.23M

Beta

0.90

Div Yield

-

RXRX Company Profile


Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

800

IPO Date

Apr 16, 2021

Website

RXRX Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 24Dec 23Dec 22
License and Service$58.49M$43.88M$39.68M
Grant$351.00K$699.00K$162.00K

Fiscal year ends in Dec 24 | Currency in USD

RXRX Financial Summary


Dec 24Dec 23Dec 22
Revenue$58.84M$44.58M$39.68M
Operating Income$-479.00M$-350.06M$-245.73M
Net Income$-463.66M$-328.07M$-239.42M
EBITDA$-426.72M$-299.57M$-227.66M
Basic EPS$-1.69$-1.58$-1.36
Diluted EPS$-1.69$-1.58$-1.36

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts


Q1 25May 05, 25 | 8:00 AM
Q4 24Feb 28, 25 | 8:30 AM
Q2 24Aug 09, 24 | 5:00 PM

Peer Comparison


TickerCompany
RLAYRelay Therapeutics, Inc.
RPTXRepare Therapeutics Inc.
VERVVerve Therapeutics, Inc.
SANASana Biotechnology, Inc.
ELEVElevation Oncology, Inc.
ZURAZura Bio Limited